Status:
TERMINATED
Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
Lead Sponsor:
Henry Ford Health System
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
18-90 years
Phase:
PHASE2
Brief Summary
Patients with FIGO stage III endometrial carcinoma often require multimodality adjuvant therapy to improve survival and recurrence rates; however, the optimal adjuvant therapy sequence is yet to be es...
Detailed Description
Purpose: To prospectively determine patients' quality of life (QOL) and treatment-related toxicity outcomes with adjuvant multimodality treatment (chemotherapy and radiation treatment) in women with a...
Eligibility Criteria
Inclusion
- FIGO stage III uterine carcinoma
- candidates for combined modality treatment (surgery, chemotherapy with carbo/Taxol, and radiation therapy)
Exclusion
- Patients who are not FIGO stage III
- patients with carcinosarcoma histology
- patients who are ineligible for combined modality treatment
Key Trial Info
Start Date :
February 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 27 2023
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04743999
Start Date
February 27 2020
End Date
June 27 2023
Last Update
March 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Cancer Institute
Detroit, Michigan, United States, 48202